Literature DB >> 14554089

Genotypic alteration of HAART-persistent HIV-1 reservoirs in vivo.

Joseph Kulkosky1, Julie Sullivan, Yan Xu, Anne Malin-Markham, Miguel Otero, Sandra Calarota, Jennifer Zielinski, Derek M Culnan, Roger J Pomerantz.   

Abstract

Three HIV-1-infected individuals, on virally-suppressive highly active anti-retroviral therapy (HAART), were treated in vivo with anti-retroviral inhibitor intensification and cell stimulatory therapies in attempting to eradicate latent viral reservoirs. Afterwards, the patients ceased all anti-retroviral drugs. Sequences of the V3 region of HIV-1 envelope protein (ENV) from patient peripheral blood mononuclear cell (PBMC) proviral DNA, patient blood plasma viral RNA and virion-associated RNA from viruses amplified by patient cell co-culture, were obtained before, during, and certain times after the clinical regimen. As anticipated, the V3 loop sequencing results indicate diversity in viral strain complexity among the individual patients. However, the detection of unique V3 ENV signature sequences or V3 signatures of low frequency, relative to those observed prior to therapy, indicate that the expression of specific viruses, or viruses of low abundance, can be induced through stimulation in vivo. Furthermore, this stimulation or general immune activation therapy (IAT) approach, consisting of administration of the anti-T-cell receptor antibody, OKT3, and IL-2 in vivo, appeared to have subsequently altered the genotype of the persistent viral reservoir in peripheral blood cells for two of the three patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14554089     DOI: 10.1016/s0042-6822(03)00464-1

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  5 in total

1.  IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.

Authors:  Feng-Xiang Wang; Yan Xu; Julie Sullivan; Emily Souder; Elias G Argyris; Edward A Acheampong; Jaime Fisher; Maria Sierra; Michael M Thomson; Rafael Najera; Ian Frank; Joseph Kulkosky; Roger J Pomerantz; Giuseppe Nunnari
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

2.  In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA.

Authors:  Mark Sharkey; Karine Triques; Daniel R Kuritzkes; Mario Stevenson
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

3.  A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen.

Authors:  Scott M Hammer; Heather Ribaudo; Roland Bassett; John W Mellors; Lisa M Demeter; Robert W Coombs; Judith Currier; Gene D Morse; John G Gerber; Ana I Martinez; William Spreen; Margaret A Fischl; Kathleen E Squires
Journal:  HIV Clin Trials       Date:  2010 Nov-Dec

Review 4.  Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy.

Authors:  Jeffrey S Barrett; Line Labbé; Marc Pfister
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

5.  Protein Kinase C: One Pathway towards the Eradication of Latent HIV-1 Reservoirs.

Authors:  Lisa N McKernan; David Momjian; Joseph Kulkosky
Journal:  Adv Virol       Date:  2012-03-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.